MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Neha Korde; Sham Mailankody; Eric L Smith; Nikoletta Lendvai; Hani Hassoun; Alexander Lesokhin; Malin Hultcrantz; David J. Chung; Gunjan L. Shah; Guenther Koehne; Heather Landau; Mikhail Roshal; Ahmet Dogan; Sergio A. Giralt; Donna Mastey; Nicole Evancha; Sean M. Devlin; Ola Landgren

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Neha Korde, Sham Mailankody, Eric L Smith, Nikoletta Lendvai, Hani Hassoun, Alexander Lesokhin, Malin Hultcrantz, David J. Chung, Gunjan L. Shah, Guenther Koehne, Heather Landau, Mikhail Roshal, Ahmet Dogan, Sergio A. Giralt, Donna Mastey, Nicole Evancha, Sean M. Devlin, Ola Landgren

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Dec 7 2017
Event	Blood - Duration: Jan 1 2020 → …

Conference

Conference	Blood
Period	1/1/20 → …

Disciplines

Physical Therapy
Medicine and Health Sciences
Immunology and Infectious Disease

Cite this

Korde, N., Mailankody, S., Smith, E. L., Lendvai, N., Hassoun, H., Lesokhin, A., Hultcrantz, M., Chung, D. J., Shah, G. L., Koehne, G., Landau, H., Roshal, M., Dogan, A., Giralt, S. A., Mastey, D., Evancha, N., Devlin, S. M., & Landgren, O. (2017). MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone. Blood.

Korde, N, Mailankody, S, Smith, EL, Lendvai, N, Hassoun, H, Lesokhin, A, Hultcrantz, M, Chung, DJ, Shah, GL, Koehne, G, Landau, H, Roshal, M, Dogan, A, Giralt, SA, Mastey, D, Evancha, N, Devlin, SM & Landgren, O 2017, 'MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone', Blood, 1/1/20.

@conference{4bed451e84b64ca090ea4fe46a022b75,

title = "MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone",

author = "Neha Korde and Sham Mailankody and Smith, {Eric L} and Nikoletta Lendvai and Hani Hassoun and Alexander Lesokhin and Malin Hultcrantz and Chung, {David J.} and Shah, {Gunjan L.} and Guenther Koehne and Heather Landau and Mikhail Roshal and Ahmet Dogan and Giralt, {Sergio A.} and Donna Mastey and Nicole Evancha and Devlin, {Sean M.} and Ola Landgren",

note = "Introduction Newly diagnosed multiple myeloma (NDMM) patients achieving and maintaining minimal residual disease (MRD) negativity demonstrate clinical benefit with prolonged progression-free survival and overall survival. The IMWG recently updated response criteria to include MRD guidelines. However, there is no data demonstrating the benefit of integrating MRD testing into a response adapted treatment approach.; Blood ; Conference date: 01-01-2020",

year = "2017",

month = dec,

day = "7",

language = "American English",

}

TY - CONF

T1 - MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

AU - Korde, Neha

AU - Mailankody, Sham

AU - Smith, Eric L

AU - Lendvai, Nikoletta

AU - Hassoun, Hani

AU - Lesokhin, Alexander

AU - Hultcrantz, Malin

AU - Chung, David J.

AU - Shah, Gunjan L.

AU - Koehne, Guenther

AU - Landau, Heather

AU - Roshal, Mikhail

AU - Dogan, Ahmet

AU - Giralt, Sergio A.

AU - Mastey, Donna

AU - Evancha, Nicole

AU - Devlin, Sean M.

AU - Landgren, Ola

N1 - Introduction Newly diagnosed multiple myeloma (NDMM) patients achieving and maintaining minimal residual disease (MRD) negativity demonstrate clinical benefit with prolonged progression-free survival and overall survival. The IMWG recently updated response criteria to include MRD guidelines. However, there is no data demonstrating the benefit of integrating MRD testing into a response adapted treatment approach.

PY - 2017/12/7

Y1 - 2017/12/7

UR - http://www.bloodjournal.org/content/130/Suppl_1/3133?sso-checked=true

M3 - Presentation

T2 - Blood

Y2 - 1 January 2020

ER -

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Conference

Disciplines

Other files and links

Cite this